ications, 2, 5 intralesional chemotherapy, 2 acitretin 2 and active surveillance 6 have been employed. Randomized controlled studies of different treatment modalities are lacking. The largest systematic review consisted of 113 case reports and case series (445 patients included) and reported 18 recurrent or persistent KA cases (4%), 2 but this data is prone to publication bias, as unusual cases are more likely to be reported and treatment outcomes could not be directly compared. Our study examines KA recurrence and persistence rates of different treatment approaches at a single institution. After Institutional Review Board approval, we searched the Stanford Cancer Institute Research Database from January 1998 to February 2016 using the keywords 'keratoacanthoma', 'crateriform' or 'cup-shaped' and applied the following two inclusion criteria: (i) at least one KA-positive biopsy read by a Stanford dermatopathologist and (ii) at least one dermatology visit documenting treatment of KAs. After manual chart review, 261 patients (with 363 KAs) met these criteria (Fig. 1) . 'Recurrence' was defined as regrowth of treated lesions documented as no clinically visible lesion after first treatment approach (FTA). 'Persistence' was defined as lesions clinically visible at the same anatomic location after FTA.
Average age at KA diagnosis was 73 years (SD 11Á7). Median follow-up time was 2Á3 years (range 0-17Á9). Overall resolution rate of KA was 97Á2% (353 of 363 KAs) after the FTA, with 2Á8% either recurring [four of 363 KAs (1Á1%)] or persisting [six of 363 KAs (1Á7%)]. The median size of resolved and recurring/persisting KAs was 1Á0 cm (range 0Á3-4Á5) and 1Á1 cm (range 0Á4-1Á6), respectively. There was no significant difference in age, sex, race and immunosuppression status between individuals with KAs that resolved after the FTA (n = 251 patients) and those whose KAs did not (n = 10 patients). Of the 21 patients who were immunosuppressed, 20 experienced KA resolution after FTA and one did not.
Surgical treatment by excision or Mohs surgery led to significantly lower recurrence rates (< 1%) than nonsurgical treatments, whose recurrence or persistence rates ranged from 12Á5% to 33Á3% (Fig. 1) .
To assist with patient counselling and estimation of duration needed for monitoring KAs, time to recurrence and duration of persistence after the FTA are shown in Table 1 . Median time to recurrence was 3 months (range 1Á5-7Á5) when all treatment modalities were considered. Median persistence time for persistent KAs prior to initiation of second treatment approach (STA) was 5 months (range 3Á8-11Á3). All recurrent and persistent KAs resolved after the STA, which was either Mohs surgery (n = 5) or excision (n = 5). No metastatic KA cases were found.
Median time to resolution for KAs after nonsurgical FTAs were as follows: active surveillance was 3 months (range 0Á6-17, n = 23), cryotherapy was 1Á4 months (range 1Á2-1Á7, n = 2), electrodessication and curettage was 3 months (range 1Á7-5Á0, n = 7) and medications (topical, intralesional or oral) was 6 months (range 1Á6-12Á6, n = 11).
Our data provides a single-site source of recurrence and persistence rates of KAs treated with a variety of FTAs (Fig. 1) . Although direct comparison of our data with prior systematic reviews is difficult owing to differences in methodology, differences between our data and the largest systematic review 2 to date are shown in Lastly, KAs treated with nonsurgical approaches including active surveillance can take up to 1 year to resolve. Hence, KAs persisting after 1 year would be candidates for surgical removal, although multicentre studies are needed to establish optimal duration for expectant management. Despite our retrospective study being the largest single-site study to date, limitations include lack of multivariate analysis owing to low sample size, and nonrandomized nonblinded design. 
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